SCLERODERMA

 

The endocannabinoid system of the skin in health and disease: novel perspectives and therapeutic opportunities (full – 2009)  http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2757311/?tool=pmcentrez

 

The cannabinoid receptor CB2 exerts antifibrotic effects in experimental dermal fibrosis (full – 2009)                                            http://www3.interscience.wiley.com/cgi-bin/fulltext/122290593/HTMLSTART

 

Cannabinoids inhibit fibrogenesis in diffuse systemic sclerosis fibroblasts                     (full – 2009)

http://rheumatology.oxfordjournals.org/content/48/9/1050.full

 

The cannabinoid WIN55, 212-2 abrogates dermal fibrosis in scleroderma bleomycin model.         (abst – 2010)                                 http://www.ncbi.nlm.nih.gov/pubmed/21177293

 

Targeting the cannabinoid pathway limits the development of fibrosis and autoimmunity in a mouse model of systemic sclerosis.                                                        (abst – 2010)  http://www.ncbi.nlm.nih.gov/pubmed/20508030

 

Is lipid signaling through cannabinoid 2 receptors part of a protective system? (full – 2011)                                        http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3062638/

 

Synthetic cannabinoid ajulemic acid exerts potent antifibrotic effects in experimental models of systemic sclerosis.                                                                  (abst – 2012)     http://www.ncbi.nlm.nih.gov/pubmed/22492781

 

Share a link for